News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vertex Pharmaceuticals (MA) (VRTX) Draws Collaboration Interest for Hepatitis C Combo


10/19/2012 7:42:45 AM

Vertex Pharmaceuticals Inc. (VRTX), maker of the hepatitis C drug Incivek, has received interest from other companies to collaborate on tests of one of its experimental medicines for the liver disease, Chief Executive Officer Jeffrey Leiden said.

The company’s VX-135 pill is one of the last in a class of medicines called nucleotides that may be an important part of combination therapy to treat hepatitis C after setbacks among other drugmakers, Leiden said in an interview yesterday at Vertex’s headquarters in Cambridge, Massachusetts.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES